Heterogeneity characterises inflammatory diseases and different phenotypes and endotypes
have been identified. Both innate and adaptive immunity contribute to the …

Atopic dermatitis (AD) is a chronic inflammatory skin disease with a high prevalence in the
developed countries. It is associated with atopic and non-atopic diseases, and its close …

Importance Since the increased use of dupilumab for atopic dermatitis (AD) in daily practice,
several cases have been reported on the development of cutaneous T-cell lymphomas …

Psoriasis and atopic dermatitis fall within the category of cutaneous immune-mediated
inflammatory diseases (IMIDs). The prevalence of IMIDs is increasing in industrialized …

Background and Objectives: Atopic dermatitis (AD), also known as eczema, is a common
chronic inflammatory skin condition affecting 16.5 million adults in the United States. AD is …

Baricitinib is a JAK1–2 inhibitor recently approved in Europe and Japan for the treatment of
moderate-to-severe atopic dermatitis in adult patients at doses of 2 and 4 mg daily. The aim …

Atopic dermatitis (AD) is a heterogeneous disease in terms of its phenotypical, barrier, and
immunological presentation. Emerging therapies are undoubtedly contributing to a new …

Atopic dermatitis is a common inflammatory disease with a chronic and relapsing course.
Although considered a childhood disease, it is now evident that atopic dermatitis is also …

Hormonal and immunologic changes during pregnancy can contribute to the development of
different dermatoses, the most common of which is atopic eruption of pregnancy (AEP). Of …

Introduction Janus kinases (JAK) are enzymes involved in signaling pathways that activate
the immune system. Upadacitinib, an oral small molecule, is the first JAK inhibitor approved …